Skip to content

Study · Randomized controlled trial · n = 226 · 1998

5 results

A controlled trial of desmopressin and behavioral therapy for nocturnal enuresis.

Kahan E, Morel D, Amir J, Zelcer C

Medicine1 Nov 1998Cited by 25 (Europe PMC)

PMID9854601 (opens in a new tab)DOI10.1097/00005792-199811000-00004 (opens in a new tab)PepBankPUB-09854601
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In enuretic children, Wet nights decreased 49% with DDAVP plus behavioral therapy versus 45% with behavioral therapy plus placebo, without significant adjusted differences.

    In plain wordsIn enuretic children, adding desmopressin to behavioral therapy did not significantly improve the adjusted treatment effect.

    Peptide
    Desmopressin
    Outcome
    No significant changeWet nights with added DDAVP
    Study

    n: not reported in source

    Comparator
    Behavioral therapy plus placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    20 micrograms/naris · intranasal spray · 8 weeksAs given in this study (human).

    Measurements

    Reduction in wet nights per week
    49%
    Group A, DDAVP plus behavioral therapy
    Reduction in wet nights per week
    45%
    Group B, behavioral therapy plus placebo

    Source sentences

    Summary
    After controlling for confounding factors, no significant difference in effect was noted among the 3 types of treatment during the trial period.
    5 context sentences
    Summary · context
    A significant reduction in the number of wet nights/week was registered for all 3 groups: 49% in Group A, 45% in Group B, and 19% in Group C.
    Summary · context
    Group A) DDAVP plus behavioral therapy (double-blind); Group B) behavioral therapy plus placebo (double-blind); and Group C) DDAVP alone (open group).
    Summary · context
    We randomly assigned 226 enuretic children being treated in primary care clinics of a major medical center in the largest health maintenance organization in Israel into 3 groups:
    Summary · context
    DDAVP (20 micrograms/naris) and placebo were administered by intranasal spray.
    Summary · context
    Both pharmacologic and behavioral therapy were initiated after a 2-week observation period and continued for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In enuretic children, DDAVP alone did not significantly differ from behavioral therapy plus placebo after adjustment.

    In plain wordsIn enuretic children, desmopressin alone did not significantly differ from behavioral therapy plus placebo after adjustment.

    Peptide
    Desmopressin
    Outcome
    No significant changeWet nights with DDAVP alone versus behavioral therapy
    Study

    n: not reported in source

    Comparator
    Behavioral therapy plus placebo
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    20 micrograms/naris · intranasal spray · 8 weeksAs given in this study (human).

    Measurements

    Reduction in wet nights per week
    19%
    Group C, DDAVP alone (open group)
    Reduction in wet nights per week
    45%
    Group B, behavioral therapy plus placebo

    Source sentences

    Summary
    After controlling for confounding factors, no significant difference in effect was noted among the 3 types of treatment during the trial period.
    5 context sentences
    Summary · context
    A significant reduction in the number of wet nights/week was registered for all 3 groups: 49% in Group A, 45% in Group B, and 19% in Group C.
    Summary · context
    Group A) DDAVP plus behavioral therapy (double-blind); Group B) behavioral therapy plus placebo (double-blind); and Group C) DDAVP alone (open group).
    Summary · context
    We randomly assigned 226 enuretic children being treated in primary care clinics of a major medical center in the largest health maintenance organization in Israel into 3 groups:
    Summary · context
    DDAVP (20 micrograms/naris) and placebo were administered by intranasal spray.
    Summary · context
    Both pharmacologic and behavioral therapy were initiated after a 2-week observation period and continued for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In enuretic children, DDAVP-alone results were significantly less stable at follow-up than in the other 2 groups (p = 0.015).

    In plain wordsIn enuretic children, results with desmopressin alone were less stable at follow-up than in the other 2 groups.

    Peptide
    Desmopressin
    Outcome
    DecreaseFollow-up response stability versus the other 2 groups
    Study

    n: not reported in source

    Comparator
    The other 2 groups (DDAVP plus behavioral therapy; behavioral therapy plus placebo)
    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    20 micrograms/naris · intranasal spray · 8 weeksAs given in this study (human).

    Measurements

    p value
    0.015 p value
    follow-up stability, DDAVP patients versus the other 2 groups

    Source sentences

    Summary
    However, on follow-up the results for the DDAVP patients were significantly less stable compared with the other 2 groups (p = 0.015).
    4 context sentences
    Summary · context
    Group A) DDAVP plus behavioral therapy (double-blind); Group B) behavioral therapy plus placebo (double-blind); and Group C) DDAVP alone (open group).
    Summary · context
    We randomly assigned 226 enuretic children being treated in primary care clinics of a major medical center in the largest health maintenance organization in Israel into 3 groups:
    Summary · context
    DDAVP (20 micrograms/naris) and placebo were administered by intranasal spray.
    Summary · context
    Both pharmacologic and behavioral therapy were initiated after a 2-week observation period and continued for 8 weeks.
  4. 04HumanNon-randomized trialSafety outcome

    No children withdrew from the trial, including the DDAVP-alone arm.

    In plain wordsNo children withdrew from the trial, including the desmopressin-alone arm.

    Peptide
    Desmopressin
    Outcome
    Not applicableTrial withdrawal
    Study

    n = 226

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 micrograms/naris · intranasal spray · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Minor side effects were registered, but none of the participants withdrew from the trial.
    3 context sentences
    Summary · context
    We randomly assigned 226 enuretic children being treated in primary care clinics of a major medical center in the largest health maintenance organization in Israel into 3 groups:
    Summary · context
    DDAVP (20 micrograms/naris) and placebo were administered by intranasal spray.
    Summary · context
    Both pharmacologic and behavioral therapy were initiated after a 2-week observation period and continued for 8 weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In enuretic children, wet nights decreased 19% with DDAVP alone, while all treatment groups improved.

    In plain wordsIn enuretic children, wet nights decreased 19% with desmopressin alone, while all treatment groups improved.

    Peptide
    Desmopressin
    Outcome
    DecreaseWet nights with DDAVP alone
    Study

    n: not reported in source

    Outcome group
    Urinary function · Kidney and urinary
    Studied dose
    20 micrograms/naris · intranasal spray · 8 weeksAs given in this study (human).

    Measurements

    Reduction in wet nights per week
    19%
    Group C, DDAVP alone (open group)

    Source sentences

    Summary
    A significant reduction in the number of wet nights/week was registered for all 3 groups: 49% in Group A, 45% in Group B, and 19% in Group C.
    3 context sentences
    Summary · context
    We randomly assigned 226 enuretic children being treated in primary care clinics of a major medical center in the largest health maintenance organization in Israel into 3 groups:
    Summary · context
    DDAVP (20 micrograms/naris) and placebo were administered by intranasal spray.
    Summary · context
    Both pharmacologic and behavioral therapy were initiated after a 2-week observation period and continued for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.